BC
UTHR icon

Brookfield Corp’s United Therapeutics UTHR Stock Holding History

Brookfield Corp’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,525
Closed -$7.93M – 784
2022
Q4 		$7.93M Buy
28,525
+691
+2% +$174K 0.03% 178
2022
Q3 		$5.83M Sell
27,834
-5,293
-16% -$1.18M 0.02% 253
2022
Q2 		$7.81M Buy
33,127
+26,361
+390% +$5.36M 0.03% 186
2022
Q1 		$1.21M Sell
6,766
-2,079
-24% -$396K ﹤0.01% 472
2021
Q4 		$1.91M Buy
+8,845
New +$1.74M 0.01% 338

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Brookfield Corp's UTHR Position: Q1 2023 in Review

Brookfield Corp sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 28,525 shares — an estimated $7.93M sold.

Brookfield Corp first reported a position in UTHR in Q4 2021 and held it in 5 quarters. The position peaked at $7.93M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Brookfield Corp reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Brookfield Corp sold 28,525 United Therapeutics shares in Q1 2023, an estimated $7.93M.
  • Brookfield Corp first reported a position in United Therapeutics in Q4 2021 and held it in 5 quarters.
  • Brookfield Corp's United Therapeutics position peaked at $7.93M in Q4 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.